Olive Leaf

This is the herb’s strongest indication. In a 12-week, active-controlled RCT, a standardised olive leaf extract (EFLA®943, 500 mg twice daily) lowered systolic blood pressure by about 11 mmHg in stage-1 hypertensives — statistically comparable to captopril 12.5–25 mg twice daily ^{1Reference 1Susalit et al. · 2011RCTOlive (Olea europaea) leaf extract effective in patients with stage-1 hypertension: comparison with Captopril — randomised controlled trialView study →}. A crossover RCT in pre-hypertensive men found phenolic-rich oleuropein extract cut 24-hour systolic BP by ~3.3 mmHg versus control ^{2Reference 2Lockyer et al. · 2017RCTImpact of phenolic-rich olive leaf extract on blood pressure, plasma lipids and inflammatory markers: a randomised controlled trialView study →}, and a 2025 multicentre trial (n=621) reported a 24-hour systolic reduction of ~6.4 mmHg versus baseline in treated hypertensives ^{3Reference 3Lamti et al. · 2025RCTEfficacy of olive leaf extracts in controlling blood pressure in hypertensive patients: a double-blind randomized clinical trial — multicentre RCTView study →}. A 2024 meta-analysis of cardiometabolic RCTs and a 2026 meta-analysis of oleuropein/olive leaf both support a favourable blood-pressure direction, and a 2026 RCT combining extract with potassium found a ~5.4 mmHg fall in morning home systolic BP ^{4,5,6Reference 4Fladerer-Grollitsch et al. · 2026RCTEffects of a combination of olive leaf extract and potassium on blood pressure in participants with mild to moderate hypertension: a double-blind, randomized, placebo-controlled trialView study →Reference 5Álvares et al. · 2024Meta-analysisOlive leaf extract effect on cardiometabolic risk factors: a systematic review and meta-analysis of randomized clinical trialsView study →Reference 6Câmara Rocha Menezes et al. · 2026Meta-analysisMetabolic and inflammatory effects of oleuropein and olive leaf extract: a systematic review and meta-analysisView study →}. Not every trial is positive: a combination extract (olive leaf, green coffee bean, beetroot) showed no effect on ambulatory BP, underlining how much the result depends on dose and formulation ^{7Reference 7Wong et al. · 2014RCTAntihypertensive potential of combined extracts of olive leaf, green coffee bean and beetroot: a randomized, double-blind, placebo-controlled crossover trialView study →}, whereas a citrus-plus-olive combination did lower systolic and diastolic BP alongside improved endothelial function in healthy subjects ^{29Reference 29Sánchez Macarro et al. · 2020RCTEffect of a combination of citrus flavones and flavanones and olive polyphenols for the reduction of cardiovascular disease risk: an exploratory randomized, double-blind, placebo-controlled study in healthy subjectsView study →}. Mechanistically, the hypotensive action is attributed partly to ACE inhibition — bioassay-guided fractionation of the aqueous leaf extract isolated the secoiridoid oleacein as a potent ACE inhibitor ^{19Reference 19Hansen et al. · 1996In vitroIsolation of an angiotensin converting enzyme (ACE) inhibitor from Olea europaea and Olea lancea — in vitroView study →}.

Gap: effect sizes vary widely with extract standardisation and baseline BP; there is no clear dose-response established for the traditional tea or 1:2 liquid extract.

Several blood-pressure RCTs measured lipids as secondary outcomes and found modest reductions. The captopril-comparison trial reported improved lipid profile with the extract ^{1Reference 1Susalit et al. · 2011RCTOlive (Olea europaea) leaf extract effective in patients with stage-1 hypertension: comparison with Captopril — randomised controlled trialView study →}; the pre-hypertensive crossover trial found total cholesterol down ~0.32 mmol/L, LDL down ~0.19 mmol/L and triglycerides down ~0.18 mmol/L ^{2Reference 2Lockyer et al. · 2017RCTImpact of phenolic-rich olive leaf extract on blood pressure, plasma lipids and inflammatory markers: a randomised controlled trialView study →}; and the 2026 extract-plus-potassium trial reported total cholesterol −11.1 mg/dL, LDL −6.9 mg/dL and triglycerides ~−22 mg/dL, with oxidised LDL down ~23% ^{4Reference 4Fladerer-Grollitsch et al. · 2026RCTEffects of a combination of olive leaf extract and potassium on blood pressure in participants with mild to moderate hypertension: a double-blind, randomized, placebo-controlled trialView study →}. The 2024 cardiometabolic meta-analysis found a positive lipid signal in a subset of trials ^{5Reference 5Álvares et al. · 2024Meta-analysisOlive leaf extract effect on cardiometabolic risk factors: a systematic review and meta-analysis of randomized clinical trialsView study →}. Against this, an 8-week RCT in overweight/obese adults with mildly elevated cholesterol found no significant change in any blood lipid ^{8Reference 8Stevens et al. · 2021RCTThe effect of olive leaf extract on cardiovascular health markers: a randomized placebo-controlled clinical trialView study →}.

Gap: the effect is small and inconsistent; the one trial that recruited specifically for dyslipidaemia was null, so olive leaf is not a substitute for lipid-lowering therapy.

Human trials show olive leaf can move inflammatory markers. In hypertensive patients, 12 weeks of extract significantly reduced interleukin-6, interleukin-8 and TNF-α versus placebo ^{10Reference 10Javadi et al. · 2019RCTEffects of olive leaf extract on metabolic response, liver and kidney functions and inflammatory biomarkers in hypertensive patients — randomized controlled trialView study →}; the pre-hypertensive crossover trial found interleukin-8 fell after extract intake ^{2Reference 2Lockyer et al. · 2017RCTImpact of phenolic-rich olive leaf extract on blood pressure, plasma lipids and inflammatory markers: a randomised controlled trialView study →}; and an acute crossover trial linked a single dose to reduced ex-vivo IL-8 production alongside improved vascular stiffness ^{11Reference 11Lockyer et al. · 2015RCTSecoiridoids delivered as olive leaf extract induce acute improvements in human vascular function and reduction of an inflammatory cytokine: a randomised, double-blind, placebo-controlled, cross-over trialView study →}. Mechanistically, in-vitro work identifies oleuropein as the principal anti-inflammatory constituent, suppressing TNF-α release from stimulated leukocytes ^{22Reference 22Qabaha et al. · 2018In vitroOleuropein is responsible for the major anti-inflammatory effects of olive leaf extract — in vitroView study →}.

Gap: marker changes are modest and not consistently accompanied by clinical inflammatory endpoints; trials use different extracts and cytokine panels, limiting comparability.

The clearest human evidence is a 12-week crossover RCT in middle-aged overweight men, where olive leaf polyphenols (51 mg oleuropein, ~10 mg hydroxytyrosol daily) improved insulin sensitivity by ~15% and pancreatic β-cell responsiveness by ~28% versus placebo ^{9Reference 9de Bock et al. · 2013RCTOlive (Olea europaea L.) leaf polyphenols improve insulin sensitivity in middle-aged overweight men: a randomized, placebo-controlled, crossover trialView study →}. The 2024 cardiometabolic meta-analysis found fasting glycaemia improved significantly in trials using a lower extract dose ^{5Reference 5Álvares et al. · 2024Meta-analysisOlive leaf extract effect on cardiometabolic risk factors: a systematic review and meta-analysis of randomized clinical trialsView study →}, and the large 2025 multicentre trial reported reduced blood glucose as a secondary outcome ^{3Reference 3Lamti et al. · 2025RCTEfficacy of olive leaf extracts in controlling blood pressure in hypertensive patients: a double-blind randomized clinical trial — multicentre RCTView study →}. Results are not uniform — a hypertension RCT found no significant change in glucose-metabolism parameters ^{10Reference 10Javadi et al. · 2019RCTEffects of olive leaf extract on metabolic response, liver and kidney functions and inflammatory biomarkers in hypertensive patients — randomized controlled trialView study →}, and the 2026 combination trial left fasting glucose and HbA1c unchanged despite better insulin/HOMA indices ^{4Reference 4Fladerer-Grollitsch et al. · 2026RCTEffects of a combination of olive leaf extract and potassium on blood pressure in participants with mild to moderate hypertension: a double-blind, randomized, placebo-controlled trialView study →}.

Gap: no adequately powered trial in people with type 2 diabetes; the glycaemic effect appears real but small and dose-sensitive.

A 2025 RCT in women with obesity found that adding olive leaf extract (250 mg/day) to a calorie-restricted diet lowered serum malondialdehyde (a lipid-peroxidation marker) more than diet alone, though total antioxidant capacity and liver enzymes were unchanged ^{12Reference 12Haidari et al. · 2025RCTPhenolic-rich extract of olive leaf with a hypocaloric diet alleviates oxidative stress in obese females: a randomized double-blind placebo-controlled trialView study →}. This is backed by consistent in-vitro data: olive leaf extract shows strong radical-scavenging and ferric-reducing activity that tracks its oleuropein content, with hydroxytyrosol — oleuropein’s hydrolysis product — carrying much of the antioxidant capacity ^{13,14Reference 13Lins et al. · 2018In vitroIn vitro antioxidant activity of olive leaf extract (Olea europaea L.) and its protective effect on oxidative damage in human erythrocytes — in vitroView study →Reference 14Yuan et al. · 2015In vitroEnzymatic hydrolysis of oleuropein from Olea europea (olive) leaf extract and antioxidant activities — in vitroView study →}.

Gap: most antioxidant data are in-vitro or on surrogate markers; whether the effect translates to clinically meaningful outcomes in vivo is largely untested.

Beyond blood pressure, preclinical work suggests direct cardiac and vascular protection. In cholesterol-fed rabbits, olive leaf extract reduced atherosclerotic lesion development, an effect linked to suppressed inflammatory response and improved lipid and antioxidant markers ^{15Reference 15Wang et al. · 2008AnimalThe anti-atherosclerotic effect of olive leaf extract is related to suppressed inflammatory response in rabbits with experimental atherosclerosis — animal model (rabbit)View study →}. In isolated rat hearts, oleuropein limited oxidative myocardial injury from ischaemia–reperfusion, reducing creatine-kinase release and lipid peroxidation ^{16Reference 16Manna et al. · 2004AnimalOleuropein prevents oxidative myocardial injury induced by ischemia and reperfusion — animal model (rat)View study →}, and in cardiomyocytes it reduced simulated ischaemia/reperfusion apoptosis via the reperfusion-injury salvage kinase (RISK) pathway ^{17Reference 17Zhao et al. · 2017In vitroOleuropein protects cardiomyocyte against apoptosis via activating the reperfusion injury salvage kinase pathway in vitroView study →}. A systematic review of rodent studies found a consistent, dose-related cardioprotective signal for oleuropein and olive leaf extract ^{18Reference 18Menezes et al. · 2022Systematic reviewOral administration of oleuropein and olive leaf extract has cardioprotective effects in rodents: a systematic review — animalView study →}.

Gap: all of this is animal or cell-based; there are no human trials of clinical cardiac endpoints (infarct size, arrhythmia, mortality), so the traditional cardiotonic claim remains preclinical.

Olive leaf’s reputation as an antimicrobial rests mainly on in-vitro work of modest potency. Extract and its phenolics inhibit Staphylococcus aureus and E. coli, and can potentiate ampicillin against these bacteria ^{23Reference 23Lim et al. · 2016In vitroPlant phenols as antibiotic boosters: in vitro interaction of olive leaf phenols with ampicillin — in vitroView study →}; against Candida albicans and C. dubliniensis the minimum inhibitory concentrations are high (tens of mg/mL), indicating weak direct antifungal activity ^{24Reference 24Zorić et al. · 2016In vitroOlive leaf extract activity against Candida albicans and C. dubliniensis — the in vitro viability studyView study →}. The most clinically relevant signal is a 2025 RCT in which olive leaf extract as an adjunct to standard antifungal therapy (nystatin or miconazole) improved outcomes in Candida-related oral disease ^{26Reference 26Kinkela Devčić et al. · 2025RCTBeneficial effect of olive leaf extract as an adjunct to standard antifungal therapy in treating Candida-related oral diseases — randomized controlled trialView study →}.

Gap: the in-vitro concentrations are far above what oral dosing achieves in tissue, so whole-body antibacterial or antiviral use is not supported; the one positive clinical result is as an adjunct, not a standalone treatment.

Interest here centres on oleuropein and its aglycone crossing into the brain. In a transgenic Alzheimer’s-disease mouse model, an oleuropein-rich olive leaf extract attenuated neuroinflammation and supported blood–brain-barrier integrity at a low dose ^{21Reference 21Abdallah et al. · 2022AnimalOleuropein-rich olive leaf extract attenuates neuroinflammation in the Alzheimer’s disease mouse modelView study →}. This fits a broader preclinical literature on olive polyphenols and neurodegeneration, but the whole-leaf, oral-dose translation to humans is unstudied.

Gap: single-model, single-species evidence; no human cognitive or neurological trial of olive leaf exists.

Despite heavy marketing for colds and flu, direct antiviral evidence is preclinical and thin. A 2024 study screened standardised olive leaf metabolites in silico against several SARS-CoV-2 targets and reported in-vitro activity for the extract ^{27Reference 27Majrashi et al. · 2024In vitroIn vitro biological evaluation and in silico insights into the antiviral activity of standardized olive leaves extract against SARS-CoV-2View study →}. There are no controlled human antiviral trials; the one respiratory RCT (in athletes) measured illness, not virology, and found no reduction in infection incidence ^{25Reference 25Somerville et al. · 2019RCTThe effect of olive leaf extract on upper respiratory illness in high school athletes: a randomised control trialView study →}.

Gap: no clinical antiviral data; in-silico docking and cell assays do not establish efficacy in people.

Anticancer claims rest entirely on cell-line and review-level data for isolated oleuropein, which has shown antiproliferative and pro-apoptotic effects across several cancer cell types in vitro ^{28Reference 28Zheng et al. · 2022ReviewAn updated review on the potential antineoplastic actions of oleuropein — reviewView study →}. No animal efficacy studies of the whole leaf and no human data support a therapeutic role.

Gap: constituent-level, in-vitro evidence only; this is not an indication for which olive leaf can be recommended.

Olive leaf extract has a good safety record in human trials: across multiple 8–12 week RCTs (including standardised extracts of 500–1,000 mg/day) adverse events were uncommon and comparable to placebo, and one active-controlled trial found it as well tolerated as captopril ^{1,3,4Reference 1Susalit et al. · 2011RCTOlive (Olea europaea) leaf extract effective in patients with stage-1 hypertension: comparison with Captopril — randomised controlled trialView study →Reference 3Lamti et al. · 2025RCTEfficacy of olive leaf extracts in controlling blood pressure in hypertensive patients: a double-blind randomized clinical trial — multicentre RCTView study →Reference 4Fladerer-Grollitsch et al. · 2026RCTEffects of a combination of olive leaf extract and potassium on blood pressure in participants with mild to moderate hypertension: a double-blind, randomized, placebo-controlled trialView study →}. The most credible concern is additive effects with cardiovascular medications — because olive leaf lowers blood pressure and glucose, it may compound the effect of antihypertensives, and its glycaemic action warrants caution alongside diabetes medication ^{3,9,10Reference 3Lamti et al. · 2025RCTEfficacy of olive leaf extracts in controlling blood pressure in hypertensive patients: a double-blind randomized clinical trial — multicentre RCTView study →Reference 9de Bock et al. · 2013RCTOlive (Olea europaea L.) leaf polyphenols improve insulin sensitivity in middle-aged overweight men: a randomized, placebo-controlled, crossover trialView study →Reference 10Javadi et al. · 2019RCTEffects of olive leaf extract on metabolic response, liver and kidney functions and inflammatory biomarkers in hypertensive patients — randomized controlled trialView study →}. It may also lower blood pressure meaningfully in people already at or below target ^{1,2,3Reference 1Susalit et al. · 2011RCTOlive (Olea europaea) leaf extract effective in patients with stage-1 hypertension: comparison with Captopril — randomised controlled trialView study →Reference 2Lockyer et al. · 2017RCTImpact of phenolic-rich olive leaf extract on blood pressure, plasma lipids and inflammatory markers: a randomised controlled trialView study →Reference 3Lamti et al. · 2025RCTEfficacy of olive leaf extracts in controlling blood pressure in hypertensive patients: a double-blind randomized clinical trial — multicentre RCTView study →}. Formal drug-interaction and CYP450 studies in humans are lacking, so interaction risk is inferred from pharmacology rather than measured.